Thus, we suggest that SNHG16 acts as an oncogene during PC progression by targeting the miR-302b-3p/SLC2A4 axis and that SNHG16 is expected to be a potential target for the early diagnosis and treatment of PC. Here, SLC2A4 is linked to pachyonychia congenita.